Use of CT Scans to
Diagnose Peripheral Vascular Disease Subject of New Training
Course Being Offered by
CVCTA Education and Toshiba Course Will Help Teach Detection of Disease Affecting Twenty Million People
July 5, 2007 -- TUSTIN, Calif. -- Strengthening its position as a leader in medical
education and improved patient care, Toshiba America Medical Systems,
Inc. today announced a partnership with CVCTA Education to provide
a Peripheral Vascular CTA (PV-CTA) training course. This course
will be the first of its kind to exceed current ACCF/AHA Level
2 requirements in the ACCF/AHA Clinical Competence Statement on
Cardiac Imaging with Computed Tomography and Magnetic Resonance.
Peripheral Vascular Disease (PVD) refers to diseases of the blood vessels outside
the heart and brain where there is a narrowing of vessels carrying
blood to the legs, arms, stomach and/or kidneys. The most common
type of PVD is Peripheral Arterial Disease (PAD) in which arteries
leading to these same regions develop blockages that restrict blood
circulation. PVD is common in patients predisposed to vascular
diseases, such as those suffering from diabetes. According to an
article in Cardiovascular Imaging, an estimated 20 million people
have PVD, with three to four million people going misdiagnosed
“PV-CTA is one of the most accurate and important non-invasive diagnostic tools
available to detect PVD in patients reporting symptoms and in those who are asymptomatic,” said
Doug Ryan, senior director, CT Business Unit. “Partnering with CVCTA Education
to offer a comprehensive PV-CTA educational course is a step toward ensuring
that PVD is properly detected and treated.”
The PV-CTA training course will be offered at CVCTA Training Centers in San Francisco,
New York and Houston, several times per month with the first course starting
in September. The course will use a blend of online learning and in-person training
on Toshiba’s leading Aquilion CT scanners. Students will complete six hours of
online didactics covering a review of anatomy and function, as well as findings
and reporting. Also, in one day of hands-on workstation training, the students
will be mentored on more than 25 cases of varying pathology. Students also will
work on more than 75 cases via CVCTA’s proprietary MedMind CTA training software.
Created by Dr. Peter Fail from the Cardiovascular Institute of the South and
Dr. Tony DeFrance from CVCTA, the PV-CTA course will provide students with more
than 100 mentored cases with a wide variety of pathology, therefore exceeding
the anticipated Level 2 requirements set by the ACCF and AHA. In total, the student
will receive 40 hours of CME credit.
“At CVCTA Education, we are committed to continually improving patient care by
offering state-of-the-art education to the medical community,” said Dr. Tony
DeFrance, Medical Director of CVCTA Education. “Additionally, PV-CTA will play
an important role in helping imaging centers and hospitals educate the community
on the emerging information and issues regarding the overall impact of PVD and
the value of this diagnostic tool.”
Additional information on the Toshiba’s PV-CTA course offered at CVCTA can be
found at www.medical.toshiba.com or www.cvcta.com.
CVCTA Education is a leader in the design and delivery of innovative medical educational programs. It has centers in San Francisco, New York and Houston to deliver its courses to the medical community. In addition to the new PV-CTA offering, CVCTA trains physicians in performing, post-processing and interpreting Cardiac CT angiograms. More information about CVCTA Education can be found at www.cvcta.com.
With headquarters in Tustin, Calif., Toshiba America Medical Systems markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. Toshiba Medical Systems Corporation, an independent group company of Toshiba Corporation, is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT, X-ray, Ultrasound, Nuclear Medicine, MRI and information systems. Toshiba Corporation is a leader in information and communications systems, electronic components, consumer products, and power systems. Toshiba has approximately 172,000 employees worldwide and annual sales of $62 billion.
links to news, press releases and other timely information
sources are provided as a service by Angioplasty.Org, which
is not responsible for the content found on any external
sites. Items marked with a ($$) indicate that the external
site normally restricts viewing to paid subscribers. Other
sites may require free registration.
send comments & suggestions
to "info at angioplasty dot org"
Read our Privacy statement.
Angioplasty.Org is an editorially independent informational health
which has received unrestricted educational grants from Medtronic plc,
TCROSS NEWS, Toshiba
Medical Systems, Volcano
Cardium Therapeutics, Inc. and Lenox Hill Heart and Vascular Institute of NY